Nova Biomedical issued a medical device correction Oct. 6 for its StatStrip Glucose Hospital Meter System after discovering a software defect that could cause a patient’s glucose reading to be linked to the wrong patient’s medical record.
The recall poses serious concerns for hospitalized patients, particularly those in intensive care units and diabetics who depend on accurate, real-time glucose monitoring to guide insulin dosing and other critical treatment decisions. A misattributed reading could lead to a patient receiving the wrong medication or dosage.
The correction, classified at a level equivalent to the FDA’s most serious Class I recall designation, was posted to the agency’s safety alerts database, confirming its awareness of the issue, according to the FDA listing.
The StatStrip system is a widely used bedside glucose testing platform deployed in hospitals across the country. The device is designed to interface with hospital information systems, automatically transmitting test results to individual patient records for clinical decision-making.
The software defect identified by Nova Biomedical may cause glucose results to be attributed to incorrect patient profiles within those hospital information systems, the company’s correction notice said. The error could affect any facility using the StatStrip system connected to electronic health records.
Wrong-patient errors are among the most dangerous categories of medical mistakes tracked by patient safety organizations. The Institute for Safe Medication Practices has identified misattributed lab results as a persistent risk factor in hospital-based medication errors.
Nova Biomedical is expected to provide affected hospitals with corrective software or procedural guidance to address the defect. The FDA’s posting of the correction to its public safety alerts database allows hospitals and clinicians to take immediate steps to verify glucose result accuracy pending the fix.
Hospital administrators and clinical laboratory directors at facilities using the StatStrip system are advised to review their glucose testing workflows and patient identification protocols in light of the correction.